O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4

Molecular Pharmacology

Volumn 45, Issue 2, 1994, Pages 352-358

  Relling, Mary V ^a,b   Nemec, Josef ^c   Schuetz, Erin G ^a,b   Schuetz, John D ^a,b   Gonzalez, Frank J ^d   Korzekwa, Kenneth R ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; TENIPOSIDE;

ARTICLE; CANCER; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER MICROSOME METABOLISM;

BIOTRANSFORMATION; CATALYSIS; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ERYTHROMYCIN; ETOPOSIDE; HUMANS; METHYLATION; MICROSOMES, LIVER; MIDAZOLAM; MIXED FUNCTION OXYGENASES; TENIPOSIDE;

EID: 0028009274     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Clark, P. I., and M. L. Slevin. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12:223-252 (1987).
2. Relling, M. V., R. Evans, D. Desiderio, C. Dass, and J. Nemec. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261:491-496 (1992).
3. Gonzalez, F. J. Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 45:1-38 (1990).
4. Gonzalez, F. J., C. L. Crespi, and H. V. Gelboin. cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat. Res. 247:113-127 (1991).
5. Guengerich, F. P., and T. Shimada. Human cytochrome P450 enzymes and chemical carcinogenesis, in Human Drug Metabolism: From Molecular Biology to Man (E. H. Jeffery, ed.). CRC Press, Boca Raton, FL, 5-11 (1993).
6. Okey, A. B. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45:241-298 (1990).
7. Kronbach, T., V. Fischer, and U. A. Meyer. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630-635 (1988).
8. Meier, P. J., H. K. Mueller, B. Dick, and U. A. Meyer. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:682-692 (1983).
9. Bradford, M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:248-254 (1976).
10. Gonzalez, F. J., T. Aoyama, and H. V. Gelboin. Expression of mammalian cytochrome P450 using vaccinia virus. Methods Enzymol. 206:85-92 (1991).
11. Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89-96 (1989).
12. Li, G., and H. Klotz. Inhibitory effect of omeprazole on the metabolism of midazolam in vitro. Arzneim. Forsch. 40:1105-1107 (1990).
13. Schuetz, E. G., S. A. Wrighton, S. H. Safe, and P. S. Guzelian. Regulation of cytochrome P-450p by phenobarbital and phenobarbital-like inducers in adult rat hepatocytes in primary monolayer culture and in vivo. Biochemistry 25:1124-1133 (1986).
14. Beaune, P., P. Kremers, F. Letawe-Goujon, and J. E. Gielen. Monoclonal antibodies against human liver cytochrome P-450. Biochem. Pharmacol. 34:3547-3552 (1985).
15. Wrighton, S. A., D. T. Molowa, and P. S. Guzelian. Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. Biochem. Pharmacol. 37:3053-3055 (1988).
16. Wrighton, S. A., C. Campanile, P. E. Thomas, S. L. Maines, P. B. Watkins, G. Parker, G. Mendez-Picon, M. Haniu, J. E. Shively, W. Levin, and P. S. Guzelian. Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 29:405-410 (1985).
17. Wrighton, S. A., P. E. Thomas, P. Willis, S. L. Maines, P. B. Watkins, W. Levin, and P. S. Guzelian. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J. Clin. Invest. 80:1017-1022 (1987).
18. Wrighton, S. A., P. E. Thomas, D. T. Molowa, M. Haniu, J. E. Shively, S. L. Maines, P. B. Watkins, G. Parker, G. Mendez-Picon, W. Levin, and P. S. Guzelian. Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry 25:6731-6735 (1986).
19. Watkins, P. B., S. A. Wrighton, P. Maurel, E. G. Schuetz, G. Mendez-Picon, G. A. Parker, and P. S. Guzelian. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82:6310-6314 (1985).
20. Relling, M. V., T. Aoyama, F. J. Gonzalez, and U. A. Meyer. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252:442-447 (1990).
21. Waxman, D. J., D. P. Lapenson, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and K. Korzekwa. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290:160-166 (1991).
22. Aoyama, T., S. Yamano, D. J. Waxman, D. P. Lapenson, U. A. Meyer, V. Fischer, R. Tyndale, T. Inaba, W. Kalow, H. V. Gelboin, and F. J. Gonzalez. Cytochrome P-450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264:10388-10395 (1989).
23. Aoyama, T., S. Yamano, P. S. Guzelian, H. V. Gelboin, and F. J. Gonzalez. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. USA 87:4790-4793 (1990).
24. Rettie, A. E., K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and W. F. Trager. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5:54-59 (1992).
25. Wrighton, S. A., W. R. Brian, M. A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, and M. VandenBranden. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38:207-213 (1990).
26. Gorski, J. C., S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton. Regioselective biotransformation of midazolam by the members of the human cytochrome p4503A subfamily. Biochem. Pharmacol., in press.
27. Haim, N., J. Nemec, J. Roman, and B. K. Sinha. In vitro metabolism of etoposide by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem. Pharmacol. 36:527-536 (1987).
28. Baker, D. K., M. V. Relling, C.-H. Pui, M. L. Christensen, W. E. Evans, and J. H. Rodman. Increased teniposide clearance with concomitant anticonvulsant therapy. J. Clin. Oncol. 10:311-315 (1992).
29. Ford, J. M., and W. N. Hait. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199 (1990).
30. Deuchars, K. L., and V. Ling. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin. Oncol. 16:156-165 (1989).
31. Guengerich, F. P., D. Muller-Enoch, and I. A. Blair. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30:287-295 (1986).
32. Gonzalez, F. J., B. J. Schmid, M. Umeno, O. W. McBride, J. P. Hardwick, U. A. Meyer, H. V. Gelboin, and J. R. Idle. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7:79-86 (1988).
33. Lum, B. L., S. Kaubisch, A. M. Yahanda, K. M. Adler, L. Jew, M. N. Ehsan, N. A. Brophy, J. Halsey, M. P. Gosland, and B. I. Sikic. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a Phase I trial to modulate multidrug resistance. J. Clin. Oncol 10:1635-1642 (1992).
34. Kerr, D. J., J. Graham, J. Cummings, J. G. Morrison, G. G. Thompson, M. J. Brodie, and S. B. Kaye. The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother. Pharmacol. 18:239-242 (1986).
35. Larrey, D., C. Funck-Brentano, P. Breil, J. Vitaux, C. Theodore, G. Babany, and D. Pessayre. Effects of erythromycin on hepatic drug metabolizing enzymes in humans. Biochem. Pharmacol. 32:1063-1068 (1983).
36. Larrey, D., M. Tinel, and D. Pessayre. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol. 32:1487-1493 (1983).
37. Pichard, L., I. Fabre, G. Fabre, J. Domergue, B. S. Aubert, G. Mourad, and P. Maurel. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:595-606 (1990).
38. Gascon, M.-P., and P. Dayer. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 41:573-578 (1991).
39. Brian, W. R., S. Marie-Agnes, M. Iwasaki, T. Shimada, L. S. Kaminsky, and F. P. Guengerich. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29:11280-11292 (1990).
40. Schwab, G. E., J. L. Raucy, and E. F. Johnson. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 33:493-499 (1988).
41. Rodman, J. H., M. Abromowitch, J. A. Sinkule, G. K. Rivera, and W. E. Evans. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J. Clin. Oncol. 5:1007-1014 (1987).
42. Stewart, C. F., A. G. Arbuck, R. A. Fleming, and W. E. Evans. Relation of systemic exposure to unbound etoposide and hematologic toxicity in adult cancer patients. Clin. Pharmacol. Ther. 50:385-393 (1991).
43. Evans, W. E., J. H. Rodman, M. V. Relling, W. P. Petros, C. F. Stewart, C.-H. Pui, and G. K. Rivera. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed versus relapsed acute lymphocytic leukemia. J. Pharmacol. Exp. Ther. 260:71-77 (1992).
44. Ratain, M. J., R. Mick, R. L. Schilsky, N. J. Vogelzang, and F. Berezin. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol. 9:1480-1486 (1991).
45. van Maanen, J. M. S., J. deVries, D. Pappie, E. van der Akker, M. V. M. Lafleur, J. Retèl, J. van der Greef, and H. M. Pinedo. Cytochrome P450-mediated O-demethylation: a route in the metabolic activation of etoposide. Cancer Res. 47:4658-4662 (1987).
46. Nelson, D. R., T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12:1-51 (1993).